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Abstract: Merkel cell carcinoma (MCC) is a rare and highly aggressive cutaneous carcinoma with characteristics 
of neuroendocrine tumor. We performed immunohistochemical analysis to demonstrate the presence of various 
neuropeptides within cells of MCC resected from a 75-year old woman. The cells of primary tumor of cheek were 
compared with the cells of regional right submandibular metastatic tumor which was found eight months later. A do-
uble-staining IHC for the pan-neuronal marker, PGP 9.5, and selected neuropeptides in the tissue material obtained 
from both locations was performed. Single multipolar cells in the main mass of primary tumor stained positively for 
PGP 9.5 and such neuropeptides as GAL, VIP, PACAP, NPY and CGRP. Moreover, we demonstrated for the first 
time the presence of neuropeptides in metastatic MCC cells. In the metastatic tumor, cells showing the co-localization 
of PGP-9.5 and neuropeptides were more numerous, mostly of oval shape, and significantly smaller than in the primary 
tumor. Thus, the progression of MCC may be associated with the acquisition by its cells of new morphological and 
biological features. (Folia Histochemica et Cytobiologica 2013, Vol. 51, No. 2, 168–173)
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Introduction
Merkel cell carcinoma (MCC) is a rare and highly ag-
gressive cutaneous tumor. Its true origin has not been 
proved definitively. The presence of electron-dense 
neurosecretory granules in the tumor cells led to its 
classification among the neuroendocrine carcinomas. 
As Merkel cells, which belong to the amine precursor 
uptake and decarboxylation system (APUD), are the 
only cutaneous cells that possess such granules, it is 
believed that MCC is derived from these cells [1]. The 
numerous secretory vacuoles of Merkel cells contain 
many biologically active substances such as vasoactive 
intestinal peptide (VIP), substance P (SP), calcitonin 
gen-related peptide (CGRP), galanin (GAL) and 
neuropeptide Y (NPY) [2–6]. Moreover, Merkel cells 
stain positively for the nervous and neuroendocrine 
cell markers such as protein gene-product 9.5 (PGP 
9.5) and chromogranin A [7, 8]. Interestingly, in pri-
mary MCC the presence of some neuropeptides was 
demonstrated only in a part of investigated tumors 
[9–10]. Since the presence of neuropeptides in the 
metachronous metastatic MCC tumor as well as the 
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comparison to the primary MCC tumor has not yet 
been investigated, the aim of this study was to perform 
such immunohistochemical analyses in a single case 
of MCC.
Material and methods
MCC tissue was obtained from a 75-year-old female who 
had the skin tumor of the upper part of right cheek/lower 
eyelid. Detailed clinical examinations revealed lack of any 
others diseases. The tumor was removed within the margin 
of macroscopically healthy tissues, and the loss of skin 
was reconstructed with a rotation flap. Macroscopically, 
it was a pale-cream colored tumor with the dimensions 
of 1.6×1.6×2 cm, covered with epidermis. It was dia-
gnosed by pathologist on the basis of the examination in 
hematoxylin-eosin (H&E) stained slides (Figure 1A) as 
a small cell type of MCC (small cell type of MCC), with 
immunohistochemical characteristics such as the presence 
of cytokeratine 20 (CK20)/+/ (Figure 1B), and CD56/+/, 
chromogranin /+/, synaptophysin/+/ (not shown). The 
rapid recurrence within the postoperative scar, after 6 
weeks from the first operation was observed. The recur-
rence was excised and the extensive loss of the skin was 
supplemented with plastics by free flap of the skin. 
In the course of further observation, local recurrence 
was not observed within this region, however, after 8 mon-
ths the metastatic tumour grew in the right submandibular 
area. For this reason, the patient underwent surgery and the 
tumor was removed. The histopathological assessment con-
firmed the metastasis of MCC with the same histological and 
immunohistochemical characteristics as the primary tumor. 
Immunofluorescence analysis. To assess the presence 
of neuropeptides, after histopathological assessment of 
the primary and metastatic, serial paraffin sections were 
obtained and double-stained by immunofluorescent tech-
nique to check for the presence of PGP 9.5, and several 
neuropeptides (VIP, PACAP, NPY, CGRP, GAL). For 
this purpose following primary antibodies were used: mouse 
anti-PGP–9.5, dilution 1:2000 (AbD Serotec, Kidlington, 
UK); rabbit anti-galanin, dilution 1:2000; rabbit anti
-PACAP, dilution 1:10000 (Peninsula Laborat.Inc., San 
Carlos, CA, USA); rabbit anti-CGRP, dilution 1:8000 
(SigmaAldrich, St. Louis, MO, USA); rabbit anti-NPY 
dilution 1:5000 (Biomol, Farmingdale, NY, USA); rabbit 
anti-VIP, dilution 1:5000 (Abcam, Cambridge, UK). The 
secondary antibodies used were goat anti-mouse Alexa 
Fluor 488 and goat anti-rabbit Alexa Fluor 555, both in 
dilution 1:500 (Invitrogen, Eugene, OR, USA). Control 
slides were processed without the use of primary antibo-
dies. The immunofluorescent reactions were evaluated 
in sections with the use of a confocal microscope (Zeiss 
LSM 710, Carl Zeiss MicroImaging, Wetzlar, Germany). 
Moreover, cell size was measured with the use of Zen 2011 
program (Carl Zeiss MicroImaging, Wetzlar, Germany).
Results
The microscopic observations of primary tumor 
sections showed the presence of single cells stained 
towards PGP-9.5 (Figure 2–5A) and the examined 
neuropeptides PACAP (Figure 2B), CGRP (Figure 
3B), GAL (Figure 4B), VIP (Figure 5B), and NPY 
(not shown). These cells were scattered throughout 
the tumor tissue and due to their size and clearly 
visible protrusions, they were easily recognizable in 
the main tumor mass which consisted of smaller, 
oval and immunofluorescence-negative cells. The 
neuropeptide-immunoreactive cells exhibited two 
or three processes widely branching from the cell 
body, suggestive of the multipolar cell shape. Within 
the cytoplasm of these cells granules containing 
neuropeptides were visible. The average diameter of 
the primary tumor cells was 20.5 ± 2.7 µm (mean SD, 
range 14–26 µm).
In the metastatic tumor, cells showing the co-locali-
zation of PGP-9.5 (Figure 2–5D), PACAP (Figure 2E), 
Figure 1A. Section through the MCC tumor of the lower eyelid stained with H&E. Neoplasm was composed of a mass of 
small and oval cells; epidermal coating of the tumor is also visible. × 200; B. Section stained with primary antibody against 
CK 20 (MCC marker) demonstrated the presence of this cytokeratine type in the neoplasm; characteristic reaction is 
present in the cytoplasm of cancer cells. × 400
A B
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CGRP (Figure 3E), GAL (Figure 4E), VIP (Figure 
5E) and NPY (not shown) were observed. Immu-
noreactive cells were more numerous than those in 
the primary tumor, located closer to each other and 
grouped in clusters. Most of the cells were oval; ho-
wever, slightly elongated cells were also visible. The 
cells which showed neuropeptide immunoreactivity 
were smaller than multipolar immunopositive cells 
found in the primary tumor. An average, diameter 
of these cells was 13.18 ± 1.9 µm (range 10–19 µm).
Figure 2. Sections of primary (FP, 2A–C) and metastatic (FM, 2D–F) MCC stained against PGP-9.5 (2A. D) and PACAP 
(2B, E) were examined by confocal laser scanning microscope (CLSM). Superimposition (2C, F) revealed double-labeled 
yellow/orange cancer cells. Multipolar cancer cells in primary tumor show cytoplasmic granules containing PACAP, howe-
ver, in metastatic tumor many oval neuropeptide-containing cells predominate. Bars: 2A–C, 20 µm; 2D–F, 50 µm
Figure 3. Sections of primary (FP, 3A–C) and metastatic (FM, 3D–F) MCC stained against PGP-9.5 (3A, D), CGRP (3B, 
E) and double-labeled (3C, F). Difference in number, size and shape of metastatic cancer cells in comparison to cells of 
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The origin and etiology of MCC are still controver-
sial. There are differences and similarities between 
Merkel cells and the cells of MCC. Although Mer-
kel cells are abundant in areas of skin involved in 
touch perception (e.g. finger tips), this location is 
uncommon for MCC. Moreover, the cells of MCC 
do not express the opioid peptides identified in nor-
mal Merkel cells [11]. On the other hand, ultrastruc-
tural studies revealed the presence of dense-core 
neuroendocrine granules in the cytoplasm of tumor 
Figure 4. Sections of primary (FP, 4A–C) and metastatic (FM, 4D–F) MCC stained against PGP-9.5 (4A, D), GAL (4B, 
E), and double-labeled (4C, F). In primary tumor few cancer cells express GAL, but in the metastatic tumor GAL (+) 
neoplastic cells are considerably more numerous and located close to each other. Bars: 4A–C, 20 µm; 4D–F, 50 µm
Figure 5. Sections of primary (FP, 5A–C) and metastatic (FM, 5D–F) MCC stained against PGP-9.5 (5A, D) and VIP (5B, 
E) and double-labeled (5C, F). In primary tumor only one cancer cell is visible within tumor mass, whereas in metastatic 
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cells similar to those observed in Merkel cells, thus 
suggesting association between the neoplasm and 
the normal neuroendocrine cell population of the 
skin Merkel cells [12]. An immunohistochemical 
investigation performed by Fantini and Johansson 
[6] revealed expression of CGRP, VIP, peptide hi-
stidine isoleucine amide, NPY, neurokinin A, GAL, 
SP, and somatostatin (SOM), in human cutaneous 
Merkel cells. These immunoreactivities were very 
variable in terms of the number of positively stained 
cells and intensity of staining, indicating that a com-
plex and heterogeneous immunophenotype can be 
expressed within this population of cells. Halata et 
al. [2] distinguished two groups of Merkel cells and 
suggested that Merkel cells with associated nerve 
terminals function as mechanoreceptor cells, while 
cells without contact to nerve terminals belong to 
the diffuse neuroendocrine system (DNES), do 
not function as mechanoreceptors, and are the 
origin of MCC. Results of previous investigations 
of the presence of neuropeptides in MCC cells are 
unequivocal. Some MCCs were reported to show 
positive reactions for VIP, SP, and SOM [13], 
however, Furuno et al. [14] did not observe neu-
ropeptides in the MCC of the eyelid. Our findings 
revealed the presence of single cells stained towards 
GAL, VIP, PACAP, NPY and CGRP in primary 
tumor and significantly more numerous immuno-
positive cells in the metastatic tumor tissue. These 
differences may be caused in part by the fact that 
the distribution of neuropeptides varies depending 
on the body region. High levels of immunoreactivity 
of SP, neurokinin A and CGRP in Merkel cells are 
found in areas with the greatest tactile sensation, 
intermediate levels in neck and face, whereas the lo-
west immunoreactivity was observed in Merkel cells 
in groins, arms, and thighs [15]. To our knowledge, 
there are as yet no reports analyzing the location of 
neuropeptides in metastatic MCC and comparison 
of their presence in neoplastic cells of the primary 
and metastatic tumors of the same patient. The 
differences in the morphology of immunoreactive 
cells observed by us in the primary and metastatic 
tumors may be related to the histological types of 
MCC. So far several histologic types are recogni-
zed in MCC based on the size of the cells (small, 
intermediate, large) or on the tumor’s architecture 
(solid, diffuse, or trabecular type) [16]. A large-cell 
type often has a trabecular pattern and a high den-
sity of granules at the ultrastructural level, while the 
ultrastructure of a small-cell type reveals paucity 
of granules and resemblance to skin metastases of 
small-cell lung carcinoma [17]. In contrast to a study 
by Sandel et al. [18], Skelton et al. [19] observed 
a correlation between small cell type predominance 
and poor prognosis. The small cell growth pattern 
is a characteristic feature of a one subtype of MCC 
invasion. The small cell morphology was found to 
be associated with high biological malignancy, fast 
growth, as well as early formation of metastases [20].
Neuropeptides can function as autocrine growth 
factors in cancer cells. Previous studies confirmed pre-
sence of neuropeptides in different types of cancers, 
e.g. PACAP in prostate and breast cancer or VIP and 
NPY in prostate and urinary bladder cancer [21–23]. 
Further investigations established the presence of 
neuropeptide receptors, e.g. VPAC1, VPAC2 and 
PACAP receptors, respectively, in prostate, breast 
and lung cancer tissues [24–28]. The occurrence of 
neuropeptides and their receptors within tumor may 
strongly suggest an autocrine pattern of signaling 
resulting in a faster tumor growth. In the small cell 
lung cancer (SCLC), stimulation of VPAC1 and PAC1 
receptors increased the levels of intracellular cAMP, 
as well as activated tyrosine kinase cellular pathways 
[29]. It was also shown that VIP caused the release of 
BB (bombesin)-like peptides from SCLC cells, which 
in an autocrine manner, via BB2 bombesin recep-
tors and mitogen activated protein kinase (MAPK) 
pathway increased expression of cell growth factors 
[30]. Moreover, an oncogenic impact of GAL receptor 
via elevation of intracellular ionized calcium concen-
tration was also found in SCLC [31]. Furthermore, it 
was shown that CGRP increased the invasive potential 
of prostate cancer cells partially by the enhancement of 
cell motility [32]. The previously described presence of 
neuropeptides and their receptors within Merkel cells 
of a normal epidermis may suggest a possible autocrine 
function of the neuropeptides in Merkel cells [5]. 
Microscopic observations carried out within this 
study for the first time showed the presence of GAL, 
VIP, PACAP, NPY and CGRP within cells of not only 
primary but also metastatic MCC. We also observed 
neuropeptidergic plasticity of the neoplastic cells 
comparing these two MCC locations. The increase in 
the number of phenotypically different neuropeptide-
containing cells in metastatic MCC suggests that the 
neuropeptides may accelerate tumor’s growth and 
its invasiveness. 
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